Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast cancer after conventional chemotherapy during the early stage of the disease.

2023-508550-25-00 Human pharmacology (Phase I) - Other Ended

Start 10 Dec 2018 · End 18 Mar 2025 · Status Ended · 1 EU/EEA countries · 4 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 30
Countries 1
Sites 4

Pre and post-menopausal women with resectable primary breast cancer and presence of residual disease after neoadjuvant chemotherapy

Key facts

Sponsor
Solti Group
Participant type
Patients
Age range
18-64 years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
10 Dec 2018 → 18 Mar 2025
Decision date (initial)
2024-04-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-508550-25-00
EudraCT number
2018-001300-10

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Pre and post-menopausal women with resectable primary breast cancer and presence of residual disease after neoadjuvant chemotherapy

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Solti Group

Sponsor organisation
Solti Group
Address
Calle Balmes 89 Planta 1 Puerta 2
City
Barcelona
Postcode
08008
Country
Spain

Scientific contact point

Organisation
Solti Group
Contact name
SOLTI Start-Up Group

Public contact point

Organisation
Solti Group
Contact name
SOLTI Start-Up Group

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 30 4
Rest of world 0

Investigational sites

Spain

4 sites · Ended
Hospital Clinic De Barcelona
Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Vall D Hebron
Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2018-12-10 2025-03-18 2018-12-20 2022-02-01

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-04 Spain Acceptable
2024-04-26
2024-04-26
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-09 Spain Acceptable
2024-04-26
2024-10-09
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-10-15 Spain Acceptable
2024-04-26
2024-10-15